Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cutibacterium acnes (formerly Propionibacterium acnes) is a common commensal bacterium residing predominantly in sebaceous skin regions. Its secreted proteins and lipids—including short-chain fatty acids like propionic acid—interact directly with keratinocytes, the main cell type of the epidermis. The bacterial products can modulate skin barrier properties by affecting keratinocyte tight junctions and stimulating lipid synthesis, primarily through activation of peroxisome proliferator–activated receptor–α (PPARα)[7]. They can induce oxidative stress through superoxide anion production mediated by CD36 receptors on keratinocytes, which contributes to inflammation and cell death[6]. The effect of these bacterial components is highly strain- and dose-dependent, with both potentially beneficial (barrier enhancement, innate immunity) and harmful (cytotoxicity, inflammation, barrier breakdown) outcomes depending on context[5][7][8]. Direct targeting of "C. acnes proteins and lipids" is not well defined as a pharmacological target, and the entry likely refers to a heterogeneous mixture of factors rather than to a specific molecular target; thus, it is not regarded as a canonical drug target. Note: The entry "Bacterial proteins and lipids in C. acnes; Keratinocytes" is overly broad, does not correspond to a distinct molecular entity or drug target (such as a single receptor or enzyme), and should be corrected to refer to a specific protein, lipid, pathway, or a defined host receptor in keratinocytes if used in structured biological databases[1][2][6][7][8].
Antibiotics: reduce C. acnes bacterial load, decreasing production of pathogenic proteins/lipids Retinoids: inhibit superoxide anion production, reduce inflammation and keratinocyte apoptosis[6]
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cutibacterium acnes bacterial proteins and lipids (impact on keratinocytes).